These findings indicate that CLDN1 can serve as a novel biomarker of chemotherapy-acquired resistance in colorectal cancer patients, helping to avoid the development of resistance and improving the prognoses of advanced colorectal cancer patients. This evidence concerns the gene CLDN1 and colorectal cancer.